CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status.
Carolina RubioMónica Martínez-FernándezCristina SegoviaIris LodewijkCristian Suarez-CabreraCarmen SegrellesFernando López-CalderónEster Munera-MaravillaMirentxu SantosAlejandra BernardiniRamon Garcia-EscuderoCorina LorzMaria José Gómez-RodriguezGuillermo de VelascoIrene OteroFelipe VillacampaFélix Guerrero-RamosSergio RuizFederico de la RosaSara Domínguez-RodríguezFrancisco X RealNúria MalatsDaniel CastellanoMarta DueñasJesus M ParamioPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
CDK4/6 inhibitors, alone or in combination, are a novel therapeutic strategy for patients with advanced bladder cancer previously classified as unfit for current treatment options.
Keyphrases